CARGO Therapeutics acquired by Concentra for $4.379/share plus CVR; delisting underway

CARGO Therapeutics, Inc.

Tender offer closed Aug 18 with 71.48% of shares tendered; merger completed Aug 19 under DGCL Section 251(h).
Shareholders receive $4.379 cash per share plus one nontransferable CVR per share under CVR Agreement dated Aug 19, 2025.
All stock options and RSUs accelerated; in-the-money options and RSUs cashed out with CVRs, out-of-money options cancelled for no consideration.
Board resigned; Kevin Tang appointed sole director and CEO, Michael Hearne CFO, Ryan Cole COO, Stew Kroll CDO, Thomas Wei CBO.
Shares to be delisted from Nasdaq and deregistered under Sections 12(b) and 12(g) of the Exchange Act.

item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.